Navigation path

EUROMALVAC1


Malaria

A European Malaria Vaccine Development Consortium
Framework programme:
5
Project number:
QLK2-CT-1999-01293
EC contribution:
€ 3 500 000
Duration:
36 months
Type:
RS
Starting date:
1 February 2000

Keywords: Malaria; vaccine; development

Summary:

The EUROMALVAC consortium, working in 13 laboratories in six European countries, is developing malaria vaccines inducing protective antibody responses to Plasmodium falciparum bloodstage antigens, moving leading vaccine candidates towards GMP-production and clinical trial whilst validating second and third generation candidates in its malaria vaccine R&D pipeline.

Problem:

Malaria is the most widespread vector-borne disease of humans. It is caused by protozoa (small single-celled organisms) of the genus Plasmodium, which are transmitted by the bite of infected mosquitoes. For humans, the most severe forms of the disease are caused by the species Plasmodium falciparum

There is an urgent need to develop new methods to control malaria. Mosquito control and drug therapy have been the major tools used to date, but insecticide resistance and parasite resistance to cheap, and once effective, anti-malarial compounds pose a major threat. There is no vaccine available, despite good evidence that the human body's immune system can eventually control the disease and protect against new infections in those that survive the first infection.

[+] Read More